Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07845578). This is a study registration, not published results. Lead sponsor: Novo Nordisk A/S. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 60 participants (ESTIMATED). Conditions: Obesity, Overweight. Interventions: DRUG: Semaglutide; DRUG: Placebo semaglutide; DRUG: Paracetamol. Primary outcome measures: AUC,para: The area under the paracetamol plasma concentration-time curve following a standardised meal , Day 177. Brief summary: The purpose of the study is to determine the effect of semaglutide on gastric emptying in people with obesity. Participants will receive either semaglutide or placebo, and the treatment assigned will be decided by chance. Semaglutide is a medicine that doctors can already prescribe, while placebo contains no active medicine.